Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics

该融资支持SP001的第二阶段开发，SP001是Spero从信达生物授权引进的首个免疫学候选药物。

Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside

该交易将未来乌特比齐（替比培南酯）里程碑付款和特许权使用费的即时价值释放出来，并使Spero能够参与潜在的长期商业收益。

Spero updates its cash runway guidance into the second half of 2029

Spero 将其现金跑道指引更新为至2029年下半年

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --

马萨诸塞州剑桥，2026年7月14日（环球电讯社）--

Spero Therapeutics, Inc.

斯佩罗治疗公司

(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR (HCRx). Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi™ (tebipenem pivoxil).

（纳斯达克股票代码：SPRO）是一家专注于推进免疫学和炎症领域下一代药物研发的临床阶段生物制药公司，今日宣布与KKR旗下Healthcare Royalty业务（HCRx）的关联公司达成一项1.05亿美元的非追索、非稀释性特许权使用费融资交易。根据协议，HCRx将获得与Utebzi™（替比培南匹伏酯）销售额相关的部分未来里程碑付款和特许权使用费。

The proceeds will primarily be used to support advancement of Spero’s lead immunology drug candidate, SP001, a Phase 2-ready, Fc-silent, third-generation anti-CD40L monoclonal antibody with potential for development across a range of immune-mediated diseases..

所得资金将主要用于支持推进Spero公司的领先免疫学候选药物SP001的研发。SP001是一种具备进入二期临床试验条件的、Fc静默的第三代抗CD40L单克隆抗体，有望在多种免疫介导疾病中实现开发应用。

'Over the past year, in collaboration with GSK, we successfully advanced Utebzi through FDA approval, while executing on our strategy to strengthen Spero and position the Company for its next phase of growth. This transaction further strengthens our balance sheet and provides non-dilutive capital as we embark on an immunology-focused strategy,” said Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics.

“在过去一年中，我们与葛兰素史克（GSK）合作，成功推动Utebzi获得美国食品药品监督管理局（FDA）批准，同时执行了强化Spero的战略，为公司下一阶段的增长奠定基础。此次交易进一步增强了我们的资产负债表，并在我们开启以免疫学为重点的战略之际提供了非稀释性资本。”Spero Therapeutics总裁兼首席执行官Esther Rajavelu表示。

'By unlocking immediate value from a portion of future Utebzi milestone and royalty streams, we are well positioned to execute on the clinical development for SP001 and continue building a differentiated pipeline for patients with immune-mediated diseases.”.

“通过提前释放未来Utebzi里程碑付款和特许权使用费收入中的一部分价值，我们已具备有利条件来推进SP001的临床开发，并继续为免疫介导疾病患者打造差异化的产品管线。”

The financing was completed concurrently with the execution of an

融资与以下文件的签署同时完成：

exclusive license agreement

独家许可协议

with Innovent Biologics for the SP001 asset and follows

与信达生物就SP001资产合作，并遵循

last month's U.S. approval

上月美国的批准

of Spero Therapeutics-developed Utebzi for complicated urinary tract infections. Spero Therapeutics has granted GSK an exclusive license to develop and commercialize Utebzi in all territories, except certain territories in Asia, where Meiji holds development and commercialization rights. Following the transaction, Spero updates its cash runway guidance into the second half of 2029..

用于治疗复杂性尿路感染的、由Spero Therapeutics开发的Utebzi。Spero Therapeutics已授予葛兰素史克（GSK）在除亚洲部分区域外的所有地区开发和商业化Utebzi的独家许可，而在这些亚洲区域，明治控股拥有开发和商业化权利。交易完成后，Spero将其现金跑道指引更新为至2029年下半年。

“We are pleased to partner with Spero on this acquisition of certain Utebzi milestones and royalties. As the first approved oral carbapenem therapy, Utebzi represents a meaningful innovation and value proposition for patients, physicians and payers,” said Clarke Futch, Chairman and CEO of HealthCare Royalty..

“我们很高兴与Spero合作，收购Utebzi的某些里程碑付款和特许权使用费。作为首款获批的口服碳青霉烯类疗法，Utebzi为患者、医生和支付方带来了重要的创新价值和价值主张。”HealthCare Royalty公司董事长兼首席执行官克拉克·富奇（Clarke Futch）表示。

Terms of the Agreement

协议条款

Under the terms of the agreements, HCRx will provide Spero with a $105 million payment at closing, net of original issue discount and applicable fees, in exchange for rights to anticipated payments from sales of Utebzi owing from GSK. HCRx will receive quarterly principal and interest payments, derived solely from the GSK payments due to Spero, until the loan balance is repaid. Following repayment, Spero will retain 35% of subsequent GSK payments related to sales of Utebzi, preserving potential long-term upside from the asset..

根据协议条款，HCRx 将在交易完成时向 Spero 提供一笔 1.05 亿美元的款项（扣除原始发行折扣及适用费用），以换取从 GSK 应付的 Utebzi 销售预期付款中获得的权益。HCRx 将每季度收取本金和利息付款，这些款项完全来源于 GSK 应付给 Spero 的款项，直至贷款余额清偿完毕。在贷款清偿后，Spero 将保留后续与 Utebzi 销售相关的 GSK 付款的 35%，从而保留该资产潜在的长期上行收益。

J. Wood Capital Advisors acted as Spero’s exclusive financial adviser and WilmerHale acted as legal advisor to Spero on the financing transaction. Sidley Austin LLP acted as legal advisor to HCRx.

J. Wood Capital Advisors 担任 Spero 的独家财务顾问，WilmerHale 担任 Spero 在该融资交易中的法律顾问。Sidley Austin LLP 担任 HCRx 的法律顾问。

About SP001

关于 SP001

SP001 is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, SP001 has the potential to provide a targeted non-B-cell-depleting treatment across multiple immune-mediated diseases where immune-cell interactions drive chronic inflammation, relapse, and tissue damage.

SP001 是一种第三代、全人源化、Fc 静默型 IgG1 单克隆抗体，靶向 CD40L。CD40L 是一种上游免疫激活信号，参与 T 细胞、B 细胞、抗原呈递细胞和血小板的生物学过程。通过阻断 CD40L，SP001 有望在多种免疫介导性疾病中提供一种靶向且非 B 细胞耗竭的治疗方案，这些疾病的慢性炎症、复发和组织损伤由免疫细胞相互作用驱动。

SP001 is designed to address platelet activation concerns associated with earlier anti-CD40L antibodies, while preserving key monoclonal antibody properties, including FcRn interaction that supports IgG-like half-life..

SP001旨在解决与早期抗CD40L抗体相关的血小板活化问题，同时保留关键单克隆抗体特性，包括支持IgG样半衰期的FcRn相互作用。

About HealthCare Royalty

关于医疗保健特许权使用费

HealthCare Royalty (“HCRx”) is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products.

HealthCare Royalty（“HCRx”）是一家领先的特许权收购公司，成立于2006年，由KKR & Co. Inc.（纽约证券交易所代码：KKR）控股。在过去的二十多年里，HCRx团队在投资处于商业化阶段和接近商业化阶段的生物制药资产方面积累了良好的业绩记录，已向110多种生物制药产品承诺投资超过70亿美元。

With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit .

HCRx在纽约、斯坦福德、旧金山、波士顿、伦敦和迈阿密设有办事处，通过向交易对手提供创新的资本解决方案，持续推动生物制药创新。欲了解更多信息，请访问。

https://www.hcrx.com

https://www.hcrx.com

. HEALTHCARE ROYALTY

. 医疗保健特许权使用费

®

®

, HEALTHCARE ROYALTY PARTNERS

，医疗特许权使用费合作伙伴

®

®

and HCRx

以及 HCRx

®

®

are registered trademarks of HealthCare Royalty Management, LLC.

是 HealthCare Royalty Management, LLC 的注册商标。

About Spero Therapeutics

关于Spero Therapeutics

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation for patients with serious diseases and major treatment gaps. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with a broad potential for additional immune-related conditions.

Spero Therapeutics 是一家临床阶段的生物制药公司，专注于推进免疫学和炎症领域的下一代药物研发，以满足患有严重疾病且存在重大治疗缺口患者的需求。公司的核心项目 SP001 是一种第三代 Fc 沉默型抗 CD40L 单克隆抗体，目前正率先在 IgG4 相关疾病中推进开发，并在其他免疫相关疾病领域具有广泛的应用潜力。

For more information, visit .

更多信息，请访问。

SperoTx.com

SperoTx.com

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, statements relating to the anticipated benefits of the non-dilutive royalty-backed transaction, including the anticipated use of proceeds; Spero’s expectations regarding its ability to advance SP001 into clinical development and the potential benefits thereof; anticipated cash runway, and future milestones; and the potential benefits of Spero’s agreement with Innovent.

本新闻稿包含经修订的1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。前瞻性陈述包括但不限于以下有关内容：非稀释性特许权使用费支持交易的预期收益，包括所得款项的预期用途；Spero对其将SP001推进至临床开发阶段的能力及相关潜在利益的预期；预期的现金跑道及未来里程碑；以及Spero与信达生物协议的潜在利益。

Forward-looking statements are based on Spero’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to the completion and integration of the Innovent transaction; Spero’s ability to successfully develop SP001; the timing and outcome of clinical trials and regulatory interactions; the ability to obtain and maintain regulatory approvals; potential safety, efficacy, manufacturing, supply, intellectual property, financing, competitive, and market risks; and other risks described in Spero’s filings with the Securities and Exchange Commission.

前瞻性陈述基于Spero当前的预期和假设，并受风险和不确定性的影响，这些风险和不确定性可能导致实际结果与此类陈述所表达或暗示的结果存在重大差异。这些风险和不确定性包括但不限于：与完成及整合Innovent交易相关的风险；Spero成功开发SP001的能力；临床试验的时间安排和结果以及与监管机构的互动情况；获得并维持监管批准的能力；潜在的安全性、有效性、生产、供应、知识产权、融资、竞争和市场风险；以及Spero向美国证券交易委员会提交的文件中描述的其他风险。

Spero undertakes no obligation to update any forward-looking statements, except as required by law..

Spero 不承担更新任何前瞻性陈述的义务，除非法律另有要求。

Investor Relations Contact:

投资者关系联系人：

Shai Biran, PhD

沙伊·比兰，博士

Spero Therapeutics

Spero Therapeutics

IR@Sperotherapeutics.com

IR@Sperotherapeutics.com

Media Inquiries:

媒体垂询：

media@sperotherapeutics.com

media@sperotherapeutics.com